AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-27. Numbers and descriptions here follow the published literature rather than marketing material.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
== Occurrence == The hydroxy group is pervasive in chemistry and biochemistry. Many inorganic compounds contain hydroxyl groups, including sulfuric acid, the chemical compound produced on the largest scale industrially. Hydroxy groups participate in the dehydration reactions that link simple biological molecules into long chains. The joining of a fatty acid to glycerol to form a triacylglycerol removes the −OH from the carboxy end of the fatty acid. The joining of two aldehyde sugars to form a disaccharide removes the −OH from the carboxy group at the aldehyde end of one sugar. The creation of a peptide bond to link two amino acids to make a protein removes the −OH from the carboxy group of one amino acid.
Serpins are a large group of proteins with similar structures. "Serpin" is derived from "serine protease inhibitors", which denotes the group's main characteristic, the inhibition of protease enzymes. More than 1000 serpins have been identified among humans, plants, bacteria, parasites, and some viruses. The first proteins from this group that were studied were antithrombin and antitrypsin, which are blood proteins. Scientists discovered that the two share a large number of amino acid sequences that were also common to ovalbumin. So, they thought they may be faced with a new family of proteins. Although the main role of serpins is the inhibition of proteases, they can also perform other functions, such as storage and transport, as well as the regulation of blood pressure.
Minoxidil — first-line, low dose topical drug for hair loss, can also be used orally at a high dose for hypertension; oral minoxidil has been implicated in heart problems including pericardial effusion. Monoamine oxidase inhibitors — used for treatment-resistant depression; may have potentially lethal dietary and drug interactions which may trigger hypertensive crisis and/or serotonin syndrome. Thalidomide — originally prescribed for morning sickness, withdrawn in 1961 owing to widespread incidence of severe birth defects (phocomelia or tetraamelia) after prenatal use by pregnant women; approved by the US Food and Drug Administration for erythema nodosum leprosum (ENL) in 1998, and new cases of multiple myeloma (administered with dexamethasone) in 2008; also used "off-label" for rare cancers; can cause multiple severe side effects and cannot be prescribed to pregnant women. Tolcapone — used in patients with Parkinson's disease who are not appropriate candidates for other adjunctive therapies; use is restricted due to hepatotoxicity. Vigabatrin — used for extreme treatment-resistant epilepsy; carries risk of permanent vision loss.
Mealworm larvae contain levels of potassium, copper, sodium, selenium, iron and zinc that rival those of beef. Mealworms contain essential linoleic acids. They have a greater vitamin content by weight compared to beef, B12 not included. Mealworms may be easily reared on fresh oats, wheat bran or grain, with sliced potato, carrots, or apple as a moisture source. The small amount of space required to raise mealworms has made them relevant for scalable industrialized mass production. But mealworm farming presents many challenges, including machinery clogging caused by the extremely fatty Tenebrio molitor larvae, as noted in the industrial-scale operations of Ynsect.
== External links == NAS Report: The Health Effects of Perchlorate Ingestion NRDC's criticism of NAS report Environment California report Archived 2010-06-09 at the Wayback Machine (Executive Summary with link to full text) Macho Moms: Perchlorate pollutant masculinizes fish: Science News Online, August 12, 2006 Archived February 20, 2008, at the Wayback Machine New Scientist Space Blog: Phoenix discovery may be bad for Mars life State Threatening to Sue Military over Water Pollution Archived 2005-11-09 at the Wayback Machine, Associated Press, May 19, 2003. Health Effects of Perchlorate from Spent Rocket, SpaceDaily.com, July 11, 2002. Dept of Defense, Dept of Energy, and US Environmental Protection Agency's Strategic Environmental Research and Development Program, Elimination of Perchlorate Oxidizers from Pyrotechnic Flare Compositions, 2009 Archived 2007-08-06 at the Wayback Machine
Sources: en.wikipedia.org
Tranexamic acid is a medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation. It is also used for hereditary angioedema. It is taken either by mouth, injection into a vein, or by intramuscular injection. Tranexamic acid is a synthetic analog of the amino acid lysine. It serves as an antifibrinolytic by reversibly binding four to five lysine receptor sites on plasminogen. This decreases the conversion of plasminogen to plasmin, preventing fibrin degradation and preserving the framework of fibrin's matrix structure. Tranexamic acid has roughly eight times the antifibrinolytic activity of an older analogue, ε-aminocaproic acid. Tranexamic acid also directly inhibits the activity of plasmin with weak potency (IC50 = 87 mM), and it can block the active-site of urokinase plasminogen activator (uPA) with high specificity (Ki = 2 mM), one of the highest among all the serine proteases. Side effects are rare; they include changes in color vision, seizures, blood clots, and allergic reactions. Tranexamic acid appears to be safe for use during pregnancy and breastfeeding. Tranexamic acid was first made in 1962 by Japanese researchers Shosuke and Utako Okamoto. It is on the World Health Organization's List of Essential Medicines. Tranexamic acid is available as a generic drug.
Heseltine said that his statement that further investment was "under consideration" was not just the normal euphemism for a decision that had not yet been announced, but was actually technically true, as at that time he was still talking to Hawker Siddeley and British Rail about buying part of the Hovertrain business. The row deflected attention from the committee's anger at the cancellation decision. Neave's real target, in the view of Heseltine's PPS Cecil Parkinson, was Heath, whom Neave detested and later helped to topple as party leader in 1975, but he and Sir Harry Legge-Bourke, both of whom had distinguished war records, also deplored Heseltine's cutting short of his National Service and his brashness and new money. Heath does not appear to have been overly bothered about the cancellation of Hovertrain, but was bothered about the mooted third London Airport at Maplin Sands on the Essex Coast, which was seen as a major prestige project along with the Channel Tunnel which was begun at this time. The Bill was threatened by a revolt of Tory backbenchers whose seats were affected, and Heath gave Heseltine a dressing down for his lack of energy in promoting it.
Deregulated kinase activity is a frequent cause of disease, in particular cancer, wherein kinases regulate many aspects that control cell growth, movement and death. Drugs that inhibit specific kinases are being developed to treat several diseases, and some are currently in clinical use, including Gleevec (imatinib) and Iressa (gefitinib).
== Analytical methods == Several HPLC-UV methods have been reported for valdecoxib estimation in biological samples like human urine. Valdecoxib has analytical methods for bioequivalence studies, metabolite determination, estimation of formulation, and an HPTLC method for simultaneous estimation in tablet dosage form.
Indeed, SIRT3 deacetylates and activates the mammalian mitochondrial acetyl-coA synthetase (AceCS2). Furthermore, SIRT3 and AceCS2 are found complexed with one another, suggesting a critical role for control of AceCS2 activity by SIRT3. Activation of the NMNAT2 enzyme, which catalyze an essential step in the nicotinamide adenine dinucleotide (NAD+) biosynthetic pathway by SIRT3 may be a means of inhibiting axon degeneration and dysfunction.
Sources: en.wikipedia.org
In the same month, The United Kingdom published its 10-year National AI Strategy, which states the British government "takes the long-term risk of non-aligned Artificial General Intelligence, and the unforeseeable changes that it would mean for ... the world, seriously". The strategy describes actions to assess long-term AI risks, including catastrophic risks. The British government held first major global summit on AI safety. This took place on the 1st and 2 November 2023 and was described as "an opportunity for policymakers and world leaders to consider the immediate and future risks of AI and how these risks can be mitigated via a globally coordinated approach". China Media Project stated "key aspects of its approach remain fundamentally unsafe by the standards of democratic societies worldwide", arguing that part of China's AI safety approach is focused on strengthening the Chinese Communist Party (CCP)'s information control. Government organizations, particularly in the United States, have also encouraged the development of technical AI safety research. The Intelligence Advanced Research Projects Activity initiated the TrojAI project to identify and protect against Trojan attacks on AI systems. The DARPA engages in research on explainable artificial intelligence and improving robustness against adversarial attacks. And the National Science Foundation supports the Center for Trustworthy Machine Learning, and is providing millions of dollars in funding for empirical AI safety research.
It often happens that the amount of antibody available to the researcher for their immunoprecipitation experiment is less than sufficient to saturate the agarose beads to be used in the immunoprecipitation. In these cases the researcher can end up with agarose particles that are only partially coated with antibodies, and the portion of the binding capacity of the agarose beads that is not coated with antibody is then free to bind anything that will stick, resulting in an elevated background signal due to non-specific binding of lysate components to the beads, which can make data interpretation difficult. While some may argue that for these reasons it is prudent to match the quantity of agarose (in terms of binding capacity) to the quantity of antibody that one wishes to be bound for the immunoprecipitation, a simple way to reduce the issue of non-specific binding to agarose beads and increase specificity is to preclear the lysate, which for any immunoprecipitation is highly recommended.
In the United States, caregivers for patients with Type 1 diabetes are instructed to have an unexpired glucagon emergency kit on hand at all times. A number of companies are developing glucagon injection devices with the goal of simplifying administration for caregivers and patients during severe hypoglycemic events. For many, the current standard of care (the glucagon emergency kit) is burdensome and not caregiver or patient-friendly due to the multiple steps required to administer the drug, especially during an emergency situation. To improve hypoglycemia treatment, many companies are developing more efficient glucagon delivery solutions. Xeris Pharmaceuticals, Inc. is developing the Glucagon Rescue Pen or G-Pen using a patented non-aqueous formulation of glucagon that is room-temperature stable, low-volume, and pre-mixed in an auto-injectable device (similar to an EpiPen) that takes the injection process down to two steps (as opposed to nine steps with glucagon emergency kits currently on the market). Similarly, GlucaPen, an autoinjector in development by Enject, Inc. promises to simplify the delivery of glucagon.
=== Medication === Treatments for the various forms of hair loss have only moderate success. Three medications have evidence to support their use in male pattern hair loss: finasteride, dutasteride and minoxidil. They typically work better to prevent further hair loss than to regrow lost hair. They may be used together when hair loss is progressive or further regrowth is desired after 12 months. Other medications include ketoconazole, and in female androgenic alopecia spironolactone and flutamide.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.